Search | IOVS | ARVO Journals

Showing 1 – 20 of 21

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Translational development of ikarovec’s bicistronic geographic atrophy lead AAV vector IKC159V through capsid and delivery route optimisation

Laura Vaux; Emily Warner; Kara Boyd; Peter Widdowson; Katie Binley; Andrew Osborne

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):714.

ARVO Annual Meeting Abstract June 2024

IKC159V: A bicistronic AAV gene therapy that boosts expression of PEDF and sCD46 provides greater efficacy than anti-complement-only gene therapies in murine models of geographic atrophy

Andrew Osborne; Emily Warner; Laura Vaux; Kara Boyd; Peter Widdowson; Katie Binley

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5340.

ARVO Annual Meeting Abstract June 2023

Evaluation of a novel bi-cistronic gene therapy for the treatment of geographic atrophy

Andrew Osborne; Kara Boyd; Laura Vaux; Peter Stuart Widdowson; Katie Binley; Emily Warner

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):799.

ARVO Annual Meeting Abstract June 2023

Enhanced reduction of vascular leakage with a novel bi-cistronic gene therapy versus anti-VEGF for neovascular age-related macular degeneration

Emily Warner; Kara Boyd; Laura Vaux; Peter Stuart Widdowson; Katie Binley; Andrew Osborne

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):771.

ARVO Annual Meeting Abstract June 2022

Novel bi-cistronic gene therapies for the treatment of dry age-related macular degeneration.

Kara Boyd; Katie Binley; Emily Francesca Warner; Andrew Osborne; Peter Stuart Widdowson

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):63 – A0036.

ARVO Annual Meeting Abstract June 2022

A Novel Bi-cistronic Gene Therapy for Neovascular Age-Related Macular Degeneration in Patients with Developing Subretinal Fibrosis

Andrew Osborne; Emily Francesca Warner; Kara Boyd; Peter Stuart Widdowson; Katie Binley

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):52 – A0025.

ARVO Annual Meeting Abstract June 2022

Novel Gene Therapy for the Regeneration of Schlemm's Canal for Patients with Ocular Hypertension

Katie Binley; Emily Francesca Warner; Kara Boyd; Peter Stuart Widdowson; Andrew Osborne

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):50 – A0023.

ARVO Annual Meeting Abstract June 2022

Design of Novel Multi-Cistronic AAV2 Gene Therapy Constructs for the Treatment of Diabetic Macular Edema

Emily Francesca Warner; Kara Boyd; Michael Whitehead; Peter Stuart Widdowson; Katie Binley; Andrew Osborne

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3470.

ARVO Annual Meeting Abstract June 2020

Neutralising antibody responses to intravitreally delivered AAV2 and exosome-associated AAV2 vectors are associated with a failure of repeated gene transfer following vector readministration in the ipsilateral eye

Michael Whitehead; Andrew Osborne; Peter Widdowson; Patrick Yu-Wai-Man; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2441.

ARVO Annual Meeting Abstract July 2018

Tau dysfunction in glaucoma: modulation of optic nerve axonal transport via gene therapy

Tasneem Khatib; Andrew Osborne; Peter S Widdowson; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3716.

ARVO Annual Meeting Abstract July 2018

QTA020V, a novel rAAV2 vector, reduces retinal ganglion cell body and axon loss in rats with laser-induced intraocular pressure elevation

Peter S Widdowson; Andrew Osborne; Tasneem Khatib; Katie Hall; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):6132.

ARVO Annual Meeting Abstract July 2018

Sustained up-regulation of neuroprotective intracellular signalling pathways in retinal ganglion cells following intravitreal injection of QTA020V, a novel rAAV2 vector

Andrew Osborne; Lalana Songra; Peter S Widdowson; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):6133.

ARVO Annual Meeting Abstract June 2017

Transgene expression, processing and activity following intravitreal Injection of QTA020V, a novel rAAV2 vector for retinal ganglion cell neuroprotection

Andrew Osborne; Peter S Widdowson; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2568.

ARVO Annual Meeting Abstract June 2017

Design and characterisation of an AAV2 vector aiming to achieve long term modulation of BDNF signalling as a treatment for glaucoma

Peter S Widdowson; Andrew Osborne; Alessia Tassoni; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2569.

ARVO Annual Meeting Abstract June 2017

QTA020V, a novel rAAV2 vector, delays retinal ganglion cell loss following optic nerve crush in the mouse

Keith R Martin; Andrew Osborne; Tasneem Khatib; Amanda Barber; George Kong; Peter S Widdowson

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2954.

Retina June 2013

Transduction of Photoreceptors With Equine Infectious Anemia Virus Lentiviral Vectors: Safety and Biodistribution of StarGen for Stargardt Disease

PDF

Katie Binley; Peter Widdowson; Julie Loader; Michelle Kelleher; Sharifah Iqball; Georgina Ferrige; Jackie de Belin; Marie Carlucci; Diana Angell-Manning; Felicity Hurst; Scott Ellis; James Miskin; Alcides Fernandes; Paul Wong; Rando Allikmets; Christopher Bergstrom; Thomas Aaberg; Jiong Yan; Jian Kong; Peter Gouras; Annick Prefontaine; Mark Vezina; Martin Bussieres; Stuart Naylor; Kyriacos A. Mitrophanous
TAGS: disease vectors, equine infectious anemia virus, eye, gene transfer techniques, lentiviral vector, macaca, oryctolagus cuniculus, photoreceptors, safety, spatial vectors
Invest. Ophthalmol. Vis. Sci.. 2013; 54(6):4061-4071. https://doi.org/10.1167/iovs.13-11871

ARVO Annual Meeting Abstract April 2011

Efficacy, Safety And Tolerability Of StargenTM, A Lentiviral-vector Based Gene Therapy For The Treatment Of Stargardt Disease, In Rabbits And Macaques

Peter Widdowson; Scott Ellis; Katie Binley; Martin Bussières; Annick Prefontaine; Mark Vezina; Rando Allikmets; Jian Kong; Kyriacos Mitrophanous; Stuart Naylor

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):479.

ARVO Annual Meeting Abstract April 2011

Biodistribution and Immunological Response of the Subretinally Injected Lentiviral-Vector StarGenTM in Rabbits and Macaques

Graham Price; Jackie de Belin; Julie Loader; Michelle Kelleher; James Miskin; Georgina Ferrige; Marie Carlucci; Diana Angell-Manning; Stuart Naylor; Peter Widdowson

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):482.

ARVO Annual Meeting Abstract April 2011

Biodistribution and Immunological Responses to the Lentiviral-Vector Based Gene Therapy Product RetinoStat® Following Subretinal Injection in Rabbits and Rhesus Macaques

Stuart M. Naylor; Michelle Kelleher; Julie Loader; Jackie de Belin; James Miskin; Georgina Ferrige; Marie Carlucci; Margaret Esapa; Scott Ellis; Peter Widdowson

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):484.

ARVO Annual Meeting Abstract April 2011

Safety And Tolerability Of Retinostat®, A Lentiviral-vector Based Gene Therapy Product For The Treatment Of Wet Age-related Macular Degeneration, In Rabbits And Monkeys

Scott Ellis; Peter Widdowson; Katie Binley; T. Michael Nork; Paul Miller; Vlad Bantseev; Brian Christian; Kyriacos Mitrophanous; Stuart Naylor

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):488.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Translational development of ikarovec’s bicistronic geographic atrophy lead AAV vector IKC159V through capsid and delivery route optimisation

IKC159V: A bicistronic AAV gene therapy that boosts expression of PEDF and sCD46 provides greater efficacy than anti-complement-only gene therapies in murine models of geographic atrophy

Evaluation of a novel bi-cistronic gene therapy for the treatment of geographic atrophy

Enhanced reduction of vascular leakage with a novel bi-cistronic gene therapy versus anti-VEGF for neovascular age-related macular degeneration

Novel bi-cistronic gene therapies for the treatment of dry age-related macular degeneration.

A Novel Bi-cistronic Gene Therapy for Neovascular Age-Related Macular Degeneration in Patients with Developing Subretinal Fibrosis

Novel Gene Therapy for the Regeneration of Schlemm's Canal for Patients with Ocular Hypertension

Design of Novel Multi-Cistronic AAV2 Gene Therapy Constructs for the Treatment of Diabetic Macular Edema

Neutralising antibody responses to intravitreally delivered AAV2 and exosome-associated AAV2 vectors are associated with a failure of repeated gene transfer following vector readministration in the ipsilateral eye

Tau dysfunction in glaucoma: modulation of optic nerve axonal transport via gene therapy

QTA020V, a novel rAAV2 vector, reduces retinal ganglion cell body and axon loss in rats with laser-induced intraocular pressure elevation

Sustained up-regulation of neuroprotective intracellular signalling pathways in retinal ganglion cells following intravitreal injection of QTA020V, a novel rAAV2 vector

Transgene expression, processing and activity following intravitreal Injection of QTA020V, a novel rAAV2 vector for retinal ganglion cell neuroprotection

Design and characterisation of an AAV2 vector aiming to achieve long term modulation of BDNF signalling as a treatment for glaucoma

QTA020V, a novel rAAV2 vector, delays retinal ganglion cell loss following optic nerve crush in the mouse

Transduction of Photoreceptors With Equine Infectious Anemia Virus Lentiviral Vectors: Safety and Biodistribution of StarGen for Stargardt Disease

Efficacy, Safety And Tolerability Of StargenTM, A Lentiviral-vector Based Gene Therapy For The Treatment Of Stargardt Disease, In Rabbits And Macaques

Biodistribution and Immunological Response of the Subretinally Injected Lentiviral-Vector StarGenTM in Rabbits and Macaques

Biodistribution and Immunological Responses to the Lentiviral-Vector Based Gene Therapy Product RetinoStat® Following Subretinal Injection in Rabbits and Rhesus Macaques

Safety And Tolerability Of Retinostat®, A Lentiviral-vector Based Gene Therapy Product For The Treatment Of Wet Age-related Macular Degeneration, In Rabbits And Monkeys

To View More...

You must be signed into an individual account to use this feature.